Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07210463Phase 3Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Role: lead

NCT05773053Phase 2Completed

A Study of NT 201 Doses in the Treatment of Platysma Prominence

Role: lead

NCT04177212Not ApplicableCompleted

Investigation of the Effectiveness and Safety of MRZF111 in the Treatment of Décolleté Wrinkles

Role: lead

NCT03806933Phase 2Completed

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Role: lead

All 4 trials loaded